Your browser doesn't support javascript.
loading
HER2 as a target in invasive urothelial carcinoma.
Bellmunt, Joaquim; Werner, Lillian; Bamias, Aristotle; Fay, André P; Park, Rachel S; Riester, Markus; Selvarajah, Shamini; Barletta, Justine A; Berman, David M; de Muga, Silvia; Salido, Marta; Gallardo, Enrique; Rojo, Federico; Guancial, Elizabeth A; Bambury, Richard; Mullane, Stephanie A; Choueiri, Toni K; Loda, Massimo; Stack, Edward; Rosenberg, Jonathan.
Afiliación
  • Bellmunt J; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Werner L; Department of Medical Oncology, University Hospital de Mar-IMIM, Barcelona, Spain.
  • Bamias A; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Fay AP; University of Athens and Hellenic Co-operative Oncology Group, Athens, Greece.
  • Park RS; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Riester M; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Selvarajah S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barletta JA; Center for Molecular Oncologic Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Berman DM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • de Muga S; The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Salido M; Hospital de Mar Research Institute-IMIM, Barcelona, Spain.
  • Gallardo E; Hospital de Mar Research Institute-IMIM, Barcelona, Spain.
  • Rojo F; Hospital Parc Tauli, Sabadell, Spain.
  • Guancial EA; Hospital de Mar Research Institute-IMIM, Barcelona, Spain.
  • Bambury R; IIS-Fundacion Jimenez Diaz, Madrid, Spain.
  • Mullane SA; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Choueiri TK; Memorial Sloan Kettering Cancer Center, New York City, New York.
  • Loda M; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Stack E; Bladder Cancer Center, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rosenberg J; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Cancer Med ; 4(6): 844-52, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25720673
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Receptor ErbB-2 / Mutación Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Receptor ErbB-2 / Mutación Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos